Form 4: Vaxcyte CFO Andrew Guggenhime Executes Option, Sells Shares Under 10b5-1 Plan

Vaxcyte's President and CFO, Andrew Guggenhime, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On February 18, 2025, Andrew Guggenhime, President and CFO of Vaxcyte, Inc., exercised options to acquire 8,000 shares of common stock at a price of $5.35 per share.
• Guggenhime then sold 6,182 shares at a weighted average price of $83.639, with prices ranging from $83.17 to $84.10.
• He also sold 1,818 shares at a weighted average price of $84.58, with prices ranging from $84.125 to $84.985.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on May 17, 2024.
• Following these transactions, Guggenhime directly owns 109,491 shares of Vaxcyte common stock and holds options for 246,827 shares.

Sentiment

Score: 6

Explanation: Neutral sentiment. The transactions are part of a pre-planned trading strategy, mitigating potential negative interpretations. The executive is exercising options and selling shares, which is a common practice.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.

Negatives

• The sale of shares by a high-ranking executive could be perceived negatively by some investors, although the 10b5-1 plan mitigates this concern.

Risks

• Executive stock sales can sometimes signal a lack of confidence in the company's future prospects, although this is less concerning given the pre-arranged trading plan.

Industry Context

Insider trading activity is always closely watched in the biotech industry, especially for companies like Vaxcyte that are in the development stage. The use of a 10b5-1 plan provides transparency and reduces concerns about opportunistic trading.

Comparison to Industry Standards

• Rule 10b5-1 trading plans are a common practice among executives at publicly traded companies, including those in the biotechnology sector.
• Many companies such as Moderna, BioNTech, and Novavax have executives who utilize similar plans to manage their stock holdings and avoid potential insider trading accusations.
• The specific details of these plans, such as the timing and volume of trades, can vary widely based on individual financial planning needs and company policies.

Stakeholder Impact

• The transactions could have a minor impact on shareholders due to the potential for slight price fluctuations, but the pre-arranged nature of the trades should minimize any significant concerns.

Key Dates

Keywords

Vaxcyte, Guggenhime, insider trading, Form 4, PCVX, stock options, Rule 10b5-1, stock sale, CFO